Stereotactic body radiotherapy with concurrent chemotherapy extends survival of patients with limited stage small cell lung cancer: a single-center prospective phase II study
详细信息 查看全文
- 作者：Chongyi Li (1)
Yanli Xiong (1)
Zejun Zhou (1)
Yu Peng (1)
Huan Huang (1)
Mingfang Xu (1)
Houyi Kang (2)
Bo Peng (1)
Dong Wang (1)
Xueqin Yang (1) - 关键词：Limited disease ; Small cell lung cancer ; SBRT ; Chemotherapy ; Concurrent
- 刊名：Medical Oncology
- 出版年：2014
- 出版时间：December 2014
- 年：2014
- 卷：31
- 期：12
- 全文大小：354 KB
- 参考文献：1. Jackman DM, Johnson BE. Small-cell lung cancer. Lancet. 2005;366(9494):1385-6. CrossRef
2. Stahel R, Ginsberg R, Havemann K, Hirsch F, Ihde D, Jassem J, et al. Staging and prognostic factors in small cell lung cancer: a consensus report. Lung Cancer. 1989;5(4-):119-6. CrossRef
3. Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol. 1992;10(6):890-.
4. Socinski MA, Bogart JA. Limited-stage small-cell lung cancer: the current status of combined-modality therapy. J Clin Oncol. 2007;25(26):4137-5. CrossRef
5. Baas P, Belderbos J, Senan S, Kwa H, van Boochove A. Concurrent chemotherapy (carboplatin, paclitaxel, etoposide) and involved-field radiotherapy in limited stage small cell lung cancer: a Dutch multicenter phase II study. Br J Cancer. 2006;94(5):625-0.
6. Colaco R, Sheikh H, Lorigan P, Blackhall F, Hulse P, Califano R, et al. Omitting elective nodal irradiation during thoracic irradiation in limited-stage small cell lung cancer–evidence from a phase II trial. Lung Cancer. 2012;76(1):72-. CrossRef
7. Watkins JM, Aguero EG, Wahlquist AE, Silvestri GA. Involved-field radiotherapy with concurrent chemotherapy for limited-stage small-cell lung cancer: disease control, patterns of failure and survival. J Med Imaging Radiat Oncol. 2010;54:483-. CrossRef
8. Yang ZX, Wang D, Wang G, Zhang QH, Liu JM, Peng P, et al. Clinical study of recombinant adenovirus-p53 combined with fractionated stereotactic radiotherapy for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2010;136(4):625-0. CrossRef
9. Shioyama Y, Nakamura K, Sasaki T, Ohga S, Yoshitake T, Nonoshita T, et al. Clinical results of stereotactic body radiotherapy for Stage I small-cell lung cancer: a single institutional experience. J Radiat Res. 2012;00:108-2.
10. Chi A, Liao Z, Nguyen NP, Xu J, Stea B, Komaki R. Systemic review of the patterns of failure following stereotactic body radiation therapy in early-stage non-small-cell lung cancer: clinical implications. Radiother Oncol. 2010;94(1):1-1. CrossRef
11. Le QT, Loo BW, Ho A, Cotrutz C, Koong AC, Wakelee H. Results of a phase I dose-escalation study using single-fraction stereotactic radiotherapy for lung tumors. J Thorac Oncol. 2006;1(8):802-. CrossRef
12. Janssen-Heijnen MLG, Karim-Kos HE, van der Drift MA, Groen HJM. Modest improvements of survival for patients with small cell lung cancer aged 45 to 59 years only, diagnosed in the Netherlands, 1989 to 2008. J Thorac Oncol. 2012;7(1):227-2. CrossRef
13. Xia T, Li H, Sun Q, Wang Y, Fan N, Yu Y, et al. Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable stage I/II non–small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2006;66(1):117-5. CrossRef
14. Wang J, Xia TY, Wang YJ, Li HQ, Li P, Wang JD, et al. Prospective study of epidermal growth factor receptor tyrosine kinase inhibitors concurrent with individualized radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2011;81(3):e59-5. CrossRef
15. van Loon J, De Ruysscher D, Wanders R, Boersma L, Simons J, Oellers M, et al. Selective nodal irradiation on basis of (18)FDG-PET scans in limited-disease small-cell lung cancer: a prospective study. Int J Radiat Oncol Biol Phys. 2010;77(2):329-6. CrossRef
16. Yang X, Wang D, Yang - 作者单位：Chongyi Li (1)
Yanli Xiong (1)
Zejun Zhou (1)
Yu Peng (1)
Huan Huang (1)
Mingfang Xu (1)
Houyi Kang (2)
Bo Peng (1)
Dong Wang (1)
Xueqin Yang (1)
1. Cancer Center, Daping Hospital and Research Institute of Surgery, Third Military Medical University, No.10 Changjiang Zhi Rd, Yuzhong District, Chongqing, 400042, China
2. Department of Radiology, Daping Hospital and Research Institute of Surgery, Third Military Medical University, Chongqing, China - ISSN：1559-131X
文摘
We carried out a prospective phase II study of patients with limited stage small cell lung cancer (LS-SCLC) assigned to receive stereotactic body radiotherapy (SBRT) concurrently with cisplatin-based chemotherapeutic regimen with OS and PFS as the primary study endpoints. Patients with pathologically proven LS-SCLC received 4- cycles of cisplatin 75?mg/(m2/day) given intravenously on day 1 and etoposide 80?mg/(m2/day) given intravenously on days 1-, both at 3 weekly intervals. SBRT at a dose of 4,000-,500?cGy in ten fractions was given concurrently with chemotherapy starting on day 1. The Kaplan–Meier curve and life tables were used to describe survival data. Adverse events were evaluated according to the common terminology criteria for adverse events version of the radiation therapy oncology group (RTOG). Twenty-nine patients were included and followed up for a median duration of 19 (range 10-5) months. The median OS was 27 (95?% CI 20.2-3.8)?months. The median PFS was 12 (95?% CI 4.2-9.8) months. No grade 4 adverse events were observed. Grade 3 adverse events occurred in only 5 (13.8?%, 5/29) patients. Neutropenia of any grade was observed in 6 (15?%, 6/29) patients, with grade 3 neutropenia only seen in one (3.4?%, 1/29) patient. The combination of chemotherapy and early concurrent SBRT could be a safe and effective treatment for LS-SCLC patients. Our study confirmed that SBRT with concurrent chemotherapy is another new treatment option for LS-SCLC patients.